Can treatment with Seraph 100 benefit COVID-19 patients?

Seraph 100 binds SARS-CoV-2. Clinicians reported that during and after treatment, inflammatory markers (such as IL-6, d-dimer, and ferritin) were reduced, as well as blood pressure stabilization and a reduced demand for vasopressors.

Seraph 100 has a wide range of applications and can safely reduce drug-susceptible and drug-resistant pathogens in the blood. Secondary bacterial or fungal infections from other sources are known complications of COVID-19.

Is SARS-CoV-2 in the blood?

Yes, multiple publications have confirmed the presence of SARS-CoV-2 in the blood. Virus in the blood correlates with disease severity.

Chen, Xiaohua, et al. “Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.” medRxiv (2020).

Chen, Weilie, et al. “Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity.” Emerging Microbes & Infections 9.1 (2020): 469-473.

Bermejo-Martin, Jesús F., et al. “Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.” Critical Care 24.1 (2020): 1-13.

Ram-Mohan, Nikhil, et al. “SARS-CoV-2 RNAaemia predicts clinical deterioration and extrapulmonary complications from COVID-19.” medRxiv (2020).

Fajnzylber, Jesse, et al. “SARS-CoV-2 viral load is associated with increased disease severity and mortality.” Nature communications 11.1 (2020): 1-9.